Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: A nationwide population-based study

European Journal of Neurology

Volumn 19, Issue 5, 2012, Pages 746-751

  Liu, C J ^a,b   Chang, Y S ^a,b   Teng, C J ^b   Chen, T J ^a,b   Ou, S M ^a   Tzeng, C H ^a,b   Wang, S J ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Autoimmune disease; Cancer risk; Extrathymic malignancy; Immunosuppressant; Myasthenia gravis

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; POPULATION RESEARCH; PRIORITY JOURNAL; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; COHORT STUDIES; COMMUNITY HEALTH PLANNING; FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TAIWAN; THALAMUS; YOUNG ADULT;

EID: 84859861630     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03621.x     Document Type: Article

References (29)

1. Szekanecz Z, Szekanecz É, Bakó G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology 2011; 57: 3-10.
2. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006; 18: 129-134.
3. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006; 15: 2069-2077.
4. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37: 141-149.
5. Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol 2010; 17: 913-921.
6. Díaz-Manera J, Rojas-García R, Illa I. Treatment strategies for myasthenia gravis. Expert Opin Pharmacother 2009; 10: 1329-1342.
7. Levin N, Abramsky O, Lossos A, et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci 2005; 237: 39-43.
8. Wakata N, Sugimoto H, Nomoto N, et al. Extrathymic tumors in patients with myasthenia gravis: a 35-year retrospective study. Neurologist 2006; 12: 53-55.
9. Owe JF, Daltveit AK, Gilhus NE. Does myasthenia gravis provide protection against cancer? Acta Neurol Scand Suppl 2006; 183: 33-36.
10. Papatestas AE, Osserman KE, Kark AE. The relationship between thymus and oncogenesis. A study of the incidence of non thymic malignancy in myasthenia gravis. Br J Cancer 1971; 25: 635-645.
11. Vessey MP, Doll R, Norman-Smith B, Hill ID. Thymectomy and cancer: a further report. Br J Cancer 1979; 39: 193-195.
12. Goulon M, Estournet B, Tulliez M. Myasthenia gravis and associated diseases. Int J Neurol 1980; 14: 61-72.
13. Citterio A, Beghi E, Millul A, et al. Risk factors for tumor occurrence in patients with myasthenia gravis. J Neurol 2009; 256: 1221-1227.
14. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010; 105: 1604-1609.
15. Taylor L, Hughes RA, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis. Eur J Neurol 2004; 11: 141.
16. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 148-158.
17. Gadalla SM, Rajan A, Pfeiffer R, et al. A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer 2011; 128: 2688-2694.
18. Travis LB, Boice JD Jr, Travis WD. Second primary cancers after thymoma. Int J Cancer 2003; 107: 868-870.
19. Welsh JS, Wilkins KB, Green R, et al. Association between thymoma and second neoplasms. JAMA 2000; 283: 1142-1143.
20. Wu CY, Hu HY, Pu CY, et al. Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study. Cancer 2011; 117: 618-624.
21. Tseng CH. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011; 34: 616-621.
22. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010; 28: 2952-2957.
23. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010; 102: 179-186.
24. Lin HP, Deng CY, Chou P. Diagnosis and treatment delay among pulmonary tuberculosis patients identified using the Taiwan reporting enquiry system, 2002-2006. BMC Public Health 2009; 9: 55.
25. Evoli A, Batocchi AP, Tonali P, Marciano M. Risk of cancer in patients with myasthenia gravis. Ann NY Acad Sci 1998; 841: 742-745.
26. Monden Y, Uyama T, Kimura S, Taniki T. Extrathymic malignancy in patients with myasthenia gravis. Eur J Cancer 1991; 27: 745-747.
27. Phillips LH II, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996; 47: 1233-1238.
28. Muller-Hermelink HK, Marx A. Thymoma. Curr Opin Oncol 2000; 12: 426-433.
29. Owe JF, Cvancarova M, Romi F, Gilhus NE. Extrathymic malignancies in thymoma patients with and without myasthenia gravis. J Neurol Sci 2010; 290: 66-69.